RESEARCH

ANTINEOPLASTONS

DISEASE

The study of antineoplastic peptide fractions in blood started in 1967. Dr. Burzynski’s analysis of peptides and amino acids in the blood of healthy people and patients suffering from various diseases, including cancer,  revealed significant deficiencies in peptide content in the serum of the cancer patients. Further research by the BRI team resulted in the separation of peptides in 119 fractions. These fractions were further tested for their effect on the growth of neoplastic and normal cells. Fractions that inhibited growth of neoplastic cells and did not inhibit normal cells were named  antineoplastons.

The March 22, 2004 issue of Fortune Magazine included a special report on “Why we are losing the war on Cancer.” The article points out that, although molecular biologists have unlocked much of the working of tumor cells, few of their findings have translated into better treatment or preventive measures. The percentage of Americans dying from cancer is still what it was in 1970 . . .... and in 1950.

                  

DRUG DEVELOPMENT

 NON-TOXIC SOLUTION
Initial studies concentrated on a group of antineoplastonsâ with a broad spectrum of activity. These are thought to have the capability of repressing oncogenes ( which promote cancer growth ) and stimulating tumor suppressor genes ( which inhibit cancer growth. ) Four formulations were selected for Phase II clinical studies

Atengenal   - ( Antineoplaston A10 injections )

Cengenal    - ( Antineoplaston A10 capsules )

Astugenal   - ( Antineoplaston AS2-1 injections )

Fengenal    - ( Antineoplaston AS2-1 capsules )

BRI is sponsoring clinical trials for these medications, with patients being treated at the Burzynski Clinic.

Research at BRI offers the opportunity to re-address the treatment issue in a more effective and less-toxic manner, with a revolutionary concept in research and treatment. The concept of interactive physiologic systems which can control the cell cycle and program cell death is the most promising. It is the next logical step in the rapidly expanding field of biomedicine. The innovative approach of BRI centers around expediting the development of this promising research into viable commercial products.